Researchers say the new discovery of AIDS drugs should not be overlooked in animal experiments.

category:Internet
 Researchers say the new discovery of AIDS drugs should not be overlooked in animal experiments.


In April 26th, the media made a heavy news, saying Hong Kong: new drugs can be AIDS, but drug researchers said that it is only the result of mice. It is reported that a new type of tandem bivalent broad-spectrum neutralizing antibody (bi-specificbNAb) has been developed by the research team led by the Institute of Microbiology at the Li Jiacheng School of medicine at the University of Hong Kong (Hong Kong). It can effectively inhibit all tested HIV strains and promote the removal of human derived mice. The latent infection of the cells in the body. This experiment is the result of the mouse experiment. Some reports are too exaggerated, and the media may also attract attention. If described as animal model results is more accurate. But our final goal is to achieve human experimentation and benefit patients. In April 27th, Professor Li Jiacheng, Professor of Microbiology at University of Hong Kongs School of medicine and Professor Chen Zhiwei, director of the Institute of AIDS, said the first financial statement. We mainly use genetic engineering methods to artificially transform antibody genes, which is technically an innovation. The two antibodies are linked together, and after this gene fusion, the activity of two antibodies can be expressed at the same time, and the effect is 100 times the simultaneous action of two single antibodies. At the same time, it has broad spectrum and can neutralize 124 kinds of fake virus strains. Chen Zhiwei said. According to Chen Zhiwei, his team invented a single gene coded bivalent broad-spectrum neutralization antibody and named it BiIA-SG, which has a two birds effect. By combining the CD4 protein on the host cell surface, BiIA-SG can strategically ambush HIV and protect CD4+T cells from infection. BiIA-SG not only shows powerful effect, but also effectively neutralizes 124 HIV subtypes of different genes in vitro, and can completely protect human derived mice from the infection of various HIV live viruses. In addition, the gene transfused BiIA-SG can play a continuous role in human derived mice and eliminate cells infected by HIV. Therefore, this study provides a conceptual validation of BiIA-SG as a new antibody drug for HIV prevention and immunotherapy. This research has been published in the latest issue of the Journal of clinical research, which is one of the worlds authoritative biomedical journals. This research has the function of curing AIDS. In mice, the drug was found to be injected with the drug, not to be infected with HIV, and in mice infected with HIV, after 3 months of continuous injection of the drug, the level of the virus decreased, and 42% of the mice could not find HIV in the mice. Of course, we like to be able to achieve this effect in monkeys and humans. Chen Zhiwei said. Wang Yuge, a postdoctoral fellow at BIDMC medical center in Boston, USA, believes that HIV cure has two kinds of radical cure and functional cure. Radical cure needs HIV virus protein (WB), HIVRNA and HIVDNA completely disappear, and eventually HIV antibody also completely disappears. Functional cure is also called long-term remission. It means that after stopping antiviral drugs, the virus will not rebound for a long time and will not rebound more than Hisakoshi Chikaneji. Wang Yuge said that from the 2013 Mississippi baby and the VISCONTI cohort, the examples of functional healing were all over the ear, while some early treatment queues had a high proportion of functional cure (called PTC), and the long-term remission rate of some of the RV254 and some of our laboratories could be as high as 26%. Therefore, when we see the pre clinical and clinical trials, the case of drug withdrawal is not a case, but it has become an uncommon phenomenon. So Im not surprised that the Ganges RIver monkey or patient does not rebound for a long time and is now more concerned with looking for a biomarker that does not rebound, which can make more patients take a pilot stop, thereby reducing compliance and discrimination. The search for PTC markers is also a recent project funded by NIH and amfAR. Wang Yuge said. Although there is still a long way to go from animal research to clinical applications, this breakthrough is still a successful opportunity for the human race on the road to HIV. For Chen Zhiwei, the success of the drug means that it is expected to become the first made in Hongkong. Since the introduction of anti HIV virus treatment and prevention measures in Hongkong in 2009, the number of confirmed HIV cases has doubled from 4443 in 2009 to 9091 in 2017. It is estimated that Hongkongs annual use of antiviral drugs for HIV is more than HK $550 million, which does not include the financial burden of life-long medication, drug toxicity and drug resistance. As a universal antibody drug, BiIA-SG has a significant improvement in its broad-spectrum and effectiveness. It is expected to be the first made in Hongkong and is suitable for the clinical treatment of HIV antibody drugs. Source: first financial responsibility editor: Bai Xin _NT4464 Although there is still a long way to go from animal research to clinical applications, this breakthrough is still a successful opportunity for the human race on the road to HIV. For Chen Zhiwei, the success of the drug means that it is expected to become the first made in Hongkong. Since the introduction of anti HIV virus treatment and prevention measures in Hongkong in 2009, the number of confirmed HIV cases has doubled from 4443 in 2009 to 9091 in 2017. It is estimated that Hongkongs annual use of antiviral drugs for HIV is more than HK $550 million, which does not include the financial burden of life-long medication, drug toxicity and drug resistance. As a universal antibody drug, BiIA-SG has a significant improvement in its broad-spectrum and effectiveness. It is expected to be the first made in Hongkong and is suitable for the clinical treatment of HIV antibody drugs.